Temporal changes in treatment patterns by age group and functional status before and after PD-1/L1 inhibitor approvals in advanced urothelial carcinoma.

Doshi, Gurjyot K; Li, Haojie; Burcu, Mehmet; Annavarapu, Srinivas; Wells, Karen; Imai, Kentaro; Moreno, Blanca Homet; Singhal, Puneet; Mamtani, Ronac

Doshi, Gurjyot K; Li, Haojie; Burcu, Mehmet; Annavarapu, Srinivas; Wells, Karen; Imai, Kentaro; Moreno, Blanca Homet; Singhal, Puneet; Mamtani, Ronac.

Afiliación

Doshi GK; The US Oncology Network, The Woodlands, TX, United States.
Li H; Merck & Co., Inc., Rahway, NJ, United States.
Burcu M; Merck & Co., Inc., Rahway, NJ, United States.
Annavarapu S; Ontada, The Woodlands, TX, United States.
Wells K; IQVIA, New York, NY, United States.
Imai K; Merck & Co., Inc., Rahway, NJ, United States.
Moreno BH; Merck & Co., Inc., Rahway, NJ, United States.
Singhal P; Merck & Co., Inc., Rahway, NJ, United States.
Mamtani R; Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, United States.

Front Oncol ; 13: 1210208, 2023.

Article en En | MEDLINE | ID: mdl-37849801

Palabras clave

US; advanced urothelial carcinoma; immunotherapy; observational study; real-world; treatment pattern

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Front Oncol Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos